Back

Mexiletine in drug-refractory ventricular arrhythmias: real-world effectiveness and tolerability

30 August 2026 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Mechanisms of arrhythmias and gender differences Drug Treatment of Ventricular Arrhythmias ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Helena Santos Moreira

Sao Joao University Hospital Centre, Porto (Portugal)

7 More presentations in this session

Presentation thumbnail
Accelerated biological aging increases the 10-year mortality risk in patients with coronary artery disease after percutaneous coronary intervention
Doctor M. Liu (Beijing, CN)
Abstract Slides
Presentation thumbnail
Mortality and device intervention in patients with a history of atrial fibrillation: a substudy of APPRAISE ATP
Professor G. Boriani (Modena, IT)
Abstract Slides
Presentation thumbnail
Sex differences in long-term arrhythmogenic and mortality outcomes in patients with hypertrophic cardiomyopathy: a 20-year longitudinal observational study
Doctor D. Silva (Rochester, US)
Abstract Slides
Presentation thumbnail
Immune-epicardial adiposity, associated with coronary artery disease, is modulated by semaglutide
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides
Presentation thumbnail
From systemic adiposity to local epicardial adipose tissue targets: uncovering novel mechanisms and biomarkers in atrial fibrillation
Mr S. Huang (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Mechanisms of arrhythmias and gender differences

The Event

Event poster

ESC Congress 2026

30 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Comparison between oral procainamide and mexiletine for the treatment of recurrent and refractory ventricular tachyarrhythmias.
4 April 2022
thumbnail
Congress Presentation
Mexiletine rescues the mixed phenotype in SCN5A-1795insD hiPSC-CMs
23 April 2021
thumbnail
Congress Presentation
Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator
8 April 2024
thumbnail
Congress Presentation
Protected ventricular tachycardia ablation in severe LV dysfunction: acute safety and efficacy in the real world
14 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources